Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

IMVAMUNE® Smallpox Vaccine in Adult Healthcare Personnel at Risk for Monkeypox in the Democratic Republic of the Congo

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02977715
Recruitment Status : Recruiting
First Posted : November 30, 2016
Last Update Posted : November 7, 2019
Sponsor:
Collaborators:
Ministry of Public Health, Democratic Republic of the Congo
Kinshasa School of Public Health
Bavarian Nordic
Information provided by (Responsible Party):
Centers for Disease Control and Prevention

Brief Summary:

Monkeypox is a febrile rash illness caused by the monkeypox virus. Its natural occurrence in the DRC puts healthcare and frontline workers at high risk of acquiring monkeypox virus infections that can prevent them from performing work duties, compromise the overall healthcare delivery in an already fragile system, and can result in death (case fatality estimates are approximately 10%).

This is an open-label prospective cohort study in up to 1,600 eligible healthcare workers at risk of monkeypox infection through their daily work. The study will document monkeypox exposure and infection in participants while concurrently evaluating the immunogenicity and safety of the vaccine, IMVAMUNE® (also known as MVA-BN, JYNNEOS, IMVANEX), in healthcare personnel in the DRC. Participation in the study is voluntary and open to male and female healthcare personnel ages 18 years and older in Tshuapa Province in The Democratic Republic of Congo who are at risk of monkeypox virus infection through their daily work or laboratory personnel performing diagnostic testing for monkeypox virus.


Condition or disease Intervention/treatment Phase
Monkeypox Virus Infection Biological: IMVAMUNE Phase 3

Detailed Description:

Orthopoxvirus infections produce antibody responses that are cross-protective against other viruses within the genus. It is this property of orthopoxviruses that allows a vaccine for vaccinia virus against smallpox to be used to provide protection against monkeypox. Studies performed during and in the immediate aftermath of smallpox eradication demonstrated that smallpox vaccination (with a first generation vaccine) could confer protection against infection with monkeypox virus. Newer, third generation vaccines such as IMVAMUNE, an attenuated (replication deficient) strain of vaccinia virus may offer an alternative safer source of vaccine-derived protection.

The clinical presentation of monkeypox infection is similar to smallpox, although it is less transmissible human-to-human than smallpox and less deadly (case fatality estimates for monkeypox are approximately 10%). Naturally-occurring human monkeypox is largely restricted to remote regions of the Congo Basin forest in Central Africa. This study is the first rigorous evaluation of IMVAMUNE in a region where natural Orthopoxvirus transmission occurs at appreciable and predictable rates. Healthcare and frontline workers in the DRC are currently at high risk of acquiring monkeypox virus infection that prevents them from performing work duties, compromises healthcare delivery in an already fragile system, and can result in death.

This open-label prospective cohort study in up to 1,600 healthcare personnel at risk of monkeypox infection through their daily work will document monkeypox virus exposure and infection in vaccinated participants while concurrently evaluating the immunogenicity and safety of IMVAMUNE vaccine. Study participation is voluntary and open to male and female healthcare personnel ages 18 years and older in Tshuapa Province in the DRC. Participants will receive two subcutaneous doses of IMVAMUNE vaccine on days 0 and 28. Blood samples will be obtained on days 0, 14, 28, 42, 180, 365, 545, and 730 for immunogenicity analysis. After each vaccination participants will be observed for at least thirty minutes. They will maintain an adverse event diary to record systemic and local adverse events for 7 days after each immunization. They will also record exposure to the monkeypox virus in an exposure diary that is reviewed at each follow-up visit.

The study will evaluate the proportion of participants who after being vaccinated 1) develop suspected or confirmed monkeypox infection, and 2) experience exposure to monkeypox virus. The study will also evaluate the safety and immunogenicity of IMVAMUNE.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 1600 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: An Open-Label Prospective Cohort Study of IMVAMUNE® Smallpox Vaccine in Adult Healthcare Personnel at Risk for Monkeypox in the Democratic Republic of the Congo
Actual Study Start Date : February 23, 2017
Estimated Primary Completion Date : August 2022
Estimated Study Completion Date : August 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Smallpox

Arm Intervention/treatment
Experimental: Intervention
Up to 1600 male and female healthcare personnel ages 18 years and older in Tshuapa Province in The Democratic Republic of Congo at risk for monkeypox will receive two doses of attenuated live virus smallpox vaccine (IMVAMUNE liquid formulation [n=1000 subjects] or lyophilized formulation [n=600 subjects]) administered on days 0 and 28 via subcutaneous injection (deltoid) (1 x 108 Tissue Culture Infectious Dose 50 [TCID50] per 0.5 mL)
Biological: IMVAMUNE
Two doses of attenuated live virus smallpox vaccine (IMVAMUNE liquid formulation or lyophilized formulation) administered on days 0 and 28 via subcutaneous injection (deltoid) (1 x 108 Tissue Culture Infectious Dose 50 [TCID50] per 0.5 mL)
Other Names:
  • Modified Vaccinia Ankara (MVA)
  • MVA-BN
  • JYNNEOS
  • IMVANEX




Primary Outcome Measures :
  1. Proportion of participants who develop suspected or confirmed monkeypox virus infection following receipt of IMVAMUNE [ Time Frame: 2 years following initial vaccination ]
  2. Proportion of participants who experience exposure to monkeypox virus following receipt of IMVAMUNE [ Time Frame: 2 years following initial vaccination ]

Secondary Outcome Measures :
  1. Proportion of participants who have orthopoxvirus antibody responses on days 0, 14, 28, 42, 180, 365, 545, and 730 days after the receipt of the first dose of vaccine [ Time Frame: 2 years following initial vaccination ]
  2. Distribution of geometric means (GMTs) on days 0, 14, 28, 42, 180, 365, 545, and 730 days after the receipt of the first dose of vaccine [ Time Frame: 2 years following initial vaccination ]
  3. Adverse event and serious adverse event information [ Time Frame: 2 years following initial vaccination ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Males and nonpregnant females (as indicated by a negative urine pregnancy test prior to first dose of vaccine) age 18 years and older.
  2. Healthcare personnel at risk of monkeypox infection working in the Tshuapa Province of DRC or laboratory personnel performing diagnostic testing for monkeypox at the time of enrollment
  3. Willing to adhere to infection control recommendations to the extent possible based on availability of resources.
  4. Able and willing to complete the informed consent process and study procedures (including blood sample collection, urine pregnancy test, and completion of adverse event diary and exposure forms).
  5. Available for all study visits.

Exclusion Criteria:

  1. Any history of allergy or anaphylaxis to any prior vaccines, eggs, or aminoglycosides.
  2. Current pregnancy (a negative urine pregnancy test is required for women participants who self-report as not pregnant). Enrollment for such participants may be deferred to a later time at which this criteria can be met.
  3. Acute illness that is accompanied by an axillary temperature ≥37.2°C (99.0°F) at the time of vaccination. Enrollment for such participants may be deferred to a later time at which this criteria can be met.
  4. Known experimental research agents or other vaccine within 28 days (4 weeks) prior to vaccination. Enrollment for such participants may be deferred to a later time at which this criteria can be met.
  5. Any reason the PIs suspect that data collected from this person would be incomplete or of poor quality.
  6. Any condition that the PIs suspect may place the participant at an unacceptable risk of injury or render the participant unable to meet the requirements of the protocol.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02977715


Contacts
Layout table for location contacts
Contact: Brett Petersen, MD, MPH 404-639-5464 IGE3@cdc.gov

Locations
Layout table for location information
Congo, The Democratic Republic of the
Tshuapa site Recruiting
Boende, Tshuapa, Congo, The Democratic Republic of the
Sponsors and Collaborators
Centers for Disease Control and Prevention
Ministry of Public Health, Democratic Republic of the Congo
Kinshasa School of Public Health
Bavarian Nordic
Investigators
Layout table for investigator information
Principal Investigator: Brett Petersen, MD, MPH Centers for Disease Control and Prevention
Principal Investigator: Emile Okitolonda Wemakoy, MD, PhD DRC

Publications:
Layout table for additonal information
Responsible Party: Centers for Disease Control and Prevention
ClinicalTrials.gov Identifier: NCT02977715    
Other Study ID Numbers: CDC-IRB-6859
First Posted: November 30, 2016    Key Record Dates
Last Update Posted: November 7, 2019
Last Verified: October 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Centers for Disease Control and Prevention:
Democratic Republic of the Congo
IMVAMUNE
Modified Vaccinia Ankara (MVA)
Monkeypox
Orthopoxvirus
Vaccine
Vaccinia virus
Additional relevant MeSH terms:
Layout table for MeSH terms
Smallpox
Monkeypox
Virus Diseases
Poxviridae Infections
DNA Virus Infections